|
|
|
|
|
|
Sponsors and Collaborators: |
St. Jude Children's Research Hospital Children's Hospital of Philadelphia National Cancer Institute (NCI) |
Information provided by: | St. Jude Children's Research Hospital |
ClinicalTrials.gov Identifier: | NCT00187057 |
This is a pilot/feasibility study designed to investigate the feasibility of treating children with A-T and cancer with regimens nearly as intense as non-A-T patients with cancer receive.
Condition | Intervention |
Ataxia-Telangiectasia |
Drug: vinblastine, vincristine, prednisone, daunorubicin Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase Drug: etoposide, cytarabine, mercaptopurine Drug: dexamethasone, procarbazine Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy |
Genetics Home Reference related topics: | ataxia-telangiectasia Friedreich ataxia |
MedlinePlus related topics: | Ataxia Telangiectasia Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia |
Estimated Enrollment: | 30 |
Study Start Date: | September 2002 |
Estimated Study Completion Date: | September 2012 |
Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1
Acute Lymphoblastic Leukemia (ALL) Low Risk
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
2
Acute Lymphoblastic Leukemia (ALL) - High Risk
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
3A
B-Cell Non-Hodgkins Lymphoma (Group A)
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
3B
B-Cell Non-Hodgkins Lymphoma (Group B)
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
4
Hodgkins Disease
|
Drug: vinblastine, vincristine, prednisone, daunorubicin
See Detailed Description section for details of treatment interventions.
Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
See Detailed Description section for details of treatment interventions.
Drug: etoposide, cytarabine, mercaptopurine
See Detailed Description section for details of treatment interventions.
Drug: dexamethasone, procarbazine
See Detailed Description section for details of treatment interventions.
Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
See Detailed Description section for details of treatment interventions.
|
Show Detailed Description |
Ages Eligible for Study: | up to 10 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria
• Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T)
United States, Tennessee | |||||
St. Jude Children's Research Hospital | |||||
Memphis, Tennessee, United States, 38105 |
St. Jude Children's Research Hospital |
Children's Hospital of Philadelphia |
National Cancer Institute (NCI) |
Principal Investigator: | John T. Sandlund, MD | St. Jude Children's Research Hospital |
St. Jude Children's Research Hospital 
  |
Responsible Party: | St. Jude Children's Research Hospital ( John T. Sandlund, MD/Principle Investigator ) |
Study ID Numbers: | AT-1 |
First Received: | September 12, 2005 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00187057 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|